CSPC Holdings Co., Ltd.

CSPC Pharmaceutical Group (HKEX: 1093) has confirmed receipt of a USD 1.2 billion upfront payment from AstraZeneca under the two firms’ strategic collaboration and license agreement for long-acting peptide medicines signed in January this year. The upfront fee is one of the largest single upfront payouts ever recorded in a China-originated pharma out-licensing transaction. The deal grants AstraZeneca (NYSE: AZN) access to eight drug programs and two proprietary platforms developed by the Shijiazhuang-based pharmaceutical group. Beyond the USD 1.2 billion upfront, the agreement carries up to USD 3.5 billion in development and regulatory milestones, up to USD 13.8 billion in sales-based milestones, and tiered royalties described as reaching up to double-digit percentages on annual net sales — bringing the theoretical total deal value to USD 18.5 billion across all eight programs. Deal context The eight programs span two categories: four existing assets, including the lead candidate SYH2082, a long-acting dual GLP-1 receptor and GIP receptor agonist described by CSPC as clinical-ready and advancing into Phase I, alongside three preclinical programs with undisclosed targets in obesity and type 2 diabetes. Four additional programs will be jointly originated under the collaboration framework using CSPC’s platforms, with CSPC responsible for advancing them through Phase I before AstraZeneca assumes global development leadership outside Greater China. The technology at the center of the arrangement is CSPC’s proprietary LiquidGel sustained-release delivery platform, an injectable depot system designed to achieve once-monthly dosing for peptide drugs. Based on its described characteristics — injectable as a liquid, forming a semi-solid depot at the injection site, with no reconstitution required — LiquidGel is consistent with the established class of in situ-forming injectable depot systems, in which a phase transition triggered by body temperature or solvent exchange creates a sustained-release matrix. CSPC has not publicly disclosed the precise chemistry underlying the platform. The practical significance of once-monthly dosing is material in the GLP-1 landscape, where the current standard of care — semaglutide and tirzepatide — requires weekly injections. A shift to monthly administration, if validated clinically, would represent a meaningful differentiation in patient convenience and adherence. AstraZeneca secured not only rights to the eight named programs but also the right to deploy LiquidGel across its own internal development pipeline, a provision that signals the platform is being licensed as a standalone enabling technology. Complementing the delivery platform is CSPC’s AI-driven peptide drug discovery engine, built through partnerships established in 2023 with XtalPi for quantum-mechanics-informed molecular simulation, Insilico Medicine for generative AI-based drug design, and Huawei Cloud for high-performance computing infrastructure. The platform covers target discovery through molecular screening and is described by CSPC as vertically integrated with LiquidGel, enabling co-optimization of peptide sequence and delivery formulation within a single workflow. Geographic rights are divided along a Greater China boundary: AstraZeneca holds exclusive development and commercialization rights globally outside mainland China, Hong Kong, Macau, and Taiwan, while CSPC retains full commercialization rights within Greater China. AstraZeneca holds an option to co-commercialize licensed products in Greater China following regulatory approval there, but that right is not an obligation. The USD 1.2 billion upfront stands out even against the backdrop of an unusually active period for large-scale China-to-global pharma licensing. In May 2026, Bristol Myers Squibb announced a USD 15.2 billion deal with Hengrui Pharma covering 13 early-stage oncology and hematology programs, with USD 950 million in near-term structured payments — a deal notable for its breadth but spread across a much larger program count. By comparison, CSPC’s USD 1.2 billion upfront fee for eight programs, concentrated in a single therapeutic area and anchored by a proprietary delivery platform, reflects a premium placed specifically on the LiquidGel technology and the monthly-dosing differentiation thesis. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

China’s National Medical Products Administration has granted marketing authorization to Ennituo (anbenitamab; SYS6092; KN026 ), a recombinant humanised bispecific antibody co-developed by Shanghai JMT-BIO Technology — a subsidiary of CSPC Pharmaceutical Group and Jiangsu Alphamab Biopharmaceuticals, for the treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received trastuzumab-containing therapy. The approval marks anbenitamab’s first cleared indication approval globally, and positions CSPC in a competitive second-line gastric cancer space increasingly defined by HER2-directed precision strategies. Ennituo is approved for use in combination with chemotherapy in this trastuzumab-pretreated population. Anbenitamab is an IgG1-type bispecific antibody that simultaneously engages two distinct, non-overlapping epitopes on HER2, a design intended to achieve more complete receptor blockade and enhanced internalization compared with conventional monospecific anti-HER2 agents. The molecule was originally developed by Alphamab Oncology using its proprietary CRIB heterodimer bispecific platform, with CSPC’s JMT-BIO subsidiary acquiring exclusive development and commercialisation rights for mainland China through a licensing agreement in August 2021. The approval rests primarily on data from KC-WISE, a pivotal Phase II/III trial enrolling patients with HER2-positive gastric or GEJ adenocarcinoma who had failed at least one prior line of therapy. Against standard chemotherapy alone, anbenitamab plus chemotherapy produced a progression-free survival of 7.1 months versus 2.7 months — a hazard ratio of 0.25, corresponding to a 75% reduction in the risk of disease progression or death. Overall survival reached 19.6 months in the combination arm compared with 11.5 months in the control arm (HR 0.25), a 71% reduction in mortality risk. Improvements in objective response rate and duration of response were also reported, with a safety profile described as favourable. The magnitude of the survival benefit observed in KC-WISE is notable in a disease setting where second-line options have historically offered modest gains. Anbenitamab’s dual-epitope engagement of HER2 is designed to prevent receptor re-expression and signalling through mechanisms that single-domain antibodies may not fully suppress, providing a mechanistic rationale for activity in patients who have already progressed on trastuzumab-based regimens. The most direct comparator in this space is fam-trastuzumab deruxtecan (Enhertu, T-DXd), the HER2-directed antibody-drug conjugate developed by Daiichi Sankyo and AstraZeneca, which carries FDA approval for HER2-positive gastric and GEJ adenocarcinoma in the post-trastuzumab setting based on the DESTINY-Gastric programme. Ramucirumab plus paclitaxel, approved for second-line gastric cancer regardless of HER2 status, remains a standard backbone against which novel agents in this line are benchmarked. Anbenitamab’s bispecific mechanism distinguishes it from both, though head-to-head data against these agents are not available from the source material. CSPC has also indicated that anbenitamab is under evaluation in HER2-positive breast cancer. A Phase III neoadjuvant study combining anbenitamab with HB1801 — the company’s proprietary albumin-bound docetaxel formulation — met its primary endpoint of total pathological complete response rate in March 2026. Registrational first-line breast cancer data from a separate Phase III study are expected later this year, suggesting the gastric approval may serve as a regulatory foundation for a broader oncology programme. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

The CDK2 inhibitor came from a $1.33 billion deal with Ensem Therapeutics in 2023, while the MAT2A asset was from a late 2024 pact with Chinese outfit CSPC Zhongqi Pharmaceutical Technology.\n BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis trial based on new data.Four of the five cancer assets have been discontinued entirely, BeOne announced in its May 6 earnings presentation (PDF). These are the EGFR-targeting BG-60366, which was in development for lung cancer; a pan-KRAS inhibitor called BGB-53038 for lung and gastrointestinal tumors; MAT2A inhibitor BG-89894 for lung and solid tumors; and CDK2 inhibitor BG-68501, for breast and solid tumors.The CDK2 inhibitor came from a $1.33 billion deal with Ensem Therapeutics in 2023, while the MAT2A asset was from a late 2024 pact with Chinese outfit CSPC Zhongqi Pharmaceutical Technology.A study of the CCR8 antibody BGB-A3055 in solid tumors has also been terminated, but this asset has not been fully discontinued, a BeOne spokesperson confirmed to Fierce Biotech.“Following a comprehensive review against our development criteria, we have made the decision to discontinue several early-stage research assets,” the spokesperson said. “Discontinuing a specific asset does not mean we are stepping away from innovation in these target areas. We continue to pursue these targets through a multi-modality approach, with promising pipeline assets for several of these targets already being studied.” In addition, the global biopharma formerly known as BeiGene has elected to halt a phase 2 trial of BGB-45035, an IRAK4 degrader, in rheumatoid arthritis. This decision was made based on “emerging new data,” the spokesperson said.“We are in the process of analyzing the data to decide the next steps for this program,” the spokesperson added. In addition to arthritis, BGB-45035 is currently listed in phase 1 development for skin diseases in BeOne’s pipeline.The culled BGB-53038 was the only RAS inhibitor BeOne was developing. The RAS field has become red-hot in the wake of phase 3 pancreatic cancer data from Revolution Medicines, with AbbVie recently financing a candidate from Kestrel Therapeutics in a deal that could end with the Chicago pharma acquiring Kestrel outright.The cancer culls come not long after BeOne paid $20 million upfront for the right to buy a preclinical trispecific antibody from China’s Huahui Health. The deal to potentially get its hands on the molecule, which targets PD-1, CTLA-4 and VEGF-A, could reach a total value of $2 billion.